Towa Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Towa Pharmaceutical has a total shareholder equity of ¥163.0B and total debt of ¥213.1B, which brings its debt-to-equity ratio to 130.8%. Its total assets and total liabilities are ¥451.2B and ¥288.2B respectively. Towa Pharmaceutical's EBIT is ¥19.2B making its interest coverage ratio 20.7. It has cash and short-term investments of ¥35.0B.
Key information
130.8%
Debt to equity ratio
JP¥213.12b
Debt
| Interest coverage ratio | 20.7x |
| Cash | JP¥35.04b |
| Equity | JP¥162.99b |
| Total liabilities | JP¥288.24b |
| Total assets | JP¥451.23b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6QC's short term assets (¥234.8B) exceed its short term liabilities (¥80.0B).
Long Term Liabilities: 6QC's short term assets (¥234.8B) exceed its long term liabilities (¥208.2B).
Debt to Equity History and Analysis
Debt Level: 6QC's net debt to equity ratio (109.3%) is considered high.
Reducing Debt: 6QC's debt to equity ratio has increased from 68.4% to 130.8% over the past 5 years.
Debt Coverage: 6QC's debt is not well covered by operating cash flow (5%).
Interest Coverage: 6QC's interest payments on its debt are well covered by EBIT (20.7x coverage).